Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal ...

Retrieved on: 2020-12-22 13:30:00

Tags for this article:

Life Sciences

Articles

Biotechnology

Communication

Forward-looking statement

SEC filings

United States corporate law

Biopharmaceutical

Dermatitis

Food and Drug Administration

Atopic dermatitis

Risk

Kindred Biosciences Inc

Click the tags to see associated articles and topics

Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal .... View article details on HISWAI: https://www.prnewswire.com/news-releases/kindred-biosciences-initiates-pivotal-efficacy-study-of-tirnovetmab-interleukin-31-monoclonal-antibody-for-canine-atopic-dermatitis-301197089.html

Excerpt

Other programs in development for atopic dermatitis include KIND-032, a fully caninized monoclonal antibody targeting IL-4R. A second pilot study to ...

Article found on: www.prnewswire.com

View Original Article